Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...
Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...
Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) ...
NEW data from the phase 3 VAILANT trial presented at ERA 2025 Congress, highlighted the potential of pegcetacoplan to modify disease progression in patients with C3 glomerulopathy (C3G) and primary ...
Background: Pulmonary arterial hypertension (PAH) is a severe condition characterized by pulmonary vascular remodelling leading to right ventricle failure. Emerging evidence highlights inflammation as ...
This fundamental study significantly advances our understanding of how parasites evade the host complement immune system. The new cryo-EM structure of the trypanosome receptor ISG65 bound to ...
Copyright: Published by Elsevier Ltd. The complement system is recognised as a protector against blood-borne pathogens and a controller of immune system and tissue ...
Nipocalimab might lower the concentration of anti-acetylcholine receptor antibodies in people with generalized myasthenia gravis, a study shows. PHOENIX, Arizona—Nipocalimab might lower the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results